European BioPharmaceutical Review |
 |
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR |
 |
| |
|
|
| Dr Helen Tayton-Martin, Editor of EBR, introduces the penultimate issue of the year |
|
|
|
| Market differentiation and localisation are crucial to successful product launches and thereby the survival of biotech companies; Gary Muddyman of Conversis explains why All that is GILTed is Gold |
|
|
| In Taking Stock of the Future, Ian Rice at Corporate Synergy Plc outlines the major issues to be addressed by a company considering flotation as a route to fund expansion, such as the appointment of advisers, documentation, fundraising and marketing |
|
|
| In Low Country Loot: Biotech Investment in the Benelux, Yvette Verleisdonk and Jacques Meunier at NautaDutilh provide a round-up of the latest investment trends in Belgium, the Netherlands and Luxembourg, where rules to promote an investor-friendly environment have been put in place |
|
|
| Taking Scotland as an example, Alan Muir at Seven Hills Venture Partners Ltd looks at the mutual benefits of international collaboration and reports on European attitudes towards partnerships on this level, in Biotech without Borders |
|
|
| In Spin-outs: Weaving the Threads of Success, Tom Hockaday at Isis Innovation Ltd evaluates the challenges and rewards of commercialising university technology, from installing a cohesive team of adaptable, proactive individuals to devise a business plan, to realising value |
|
|
|
| European industry has long needed unified regulations to determine the freedom available to companies producing versions of innovative drugs. In Generalising Generics, Torben Ravn Rasmussen at the Internationalt Patent-Bureau A/S explores the effectiveness of the nascent Bolar Provisions |
|
|
| Named patient supply can facilitate swift access to treatment for individuals with serious conditions, in addition to providing valuable early experience of new medicines amongst healthcare professionals. In The Name Game, Natalie Douglas at IDIS looks at European regulations surrounding this practice |
|
|
| Diane J Romza-Kutz and Karen A Weaver of Epstein Becker & Green PC adopt A Practical State of Mind in their article on the teething troubles of the European Clinical Trials Directive |
|
|
| Are you REACHing Readiness? Hanna Paloheimo at Borenius and Kemppinen anticipates the 2007 enactment of the new regulations governing registration, evaluation and authorisation of chemicals |
|
|
| Dr Christof Gänzler of Spotfire explains how to avoid a quagmire of unqualified information by using visual analytics to extricate meaning and value from data, in Picture This |
|
|
|
| Dr Deepak Singh at Accelrys uncovers the conundrums and complexities of Nanodesign: Triumph in Tiny Proportions |
|
|
| The vast majority of cancer deaths worldwide are attributable to metastasis, and yet most treatments focus on the destruction of primary tumours. Professor Robert Kiss at Unibioscreen looks at the potential of current investigations into halting this mechanism, in Therapeutic Agents to Challenge Cancer Metastasis |
|
|
| Dr Alison Kerr and Dr Gordon Meiklejohn at MD Biosciences give an overview of current models and recent technological advances such as adoptive transfer, in Asthma: Measuring the Breadth of New Medicines |
|
|
| Variability is a significant problem in the reproduction of embryonic stem cells; in The Self-Renewing Solution, Solène Jamet and Patrick J Mee of Stem Cell Sciences plc survey progress towards an easier-to-use system producing uniform cells |
|
|
|
| Natural product-based research lost favour in the 1990s, due in part to the perception of combinatorial chemistry as a panacea for the drug discovery process. In Natural Selection, Phil Dudfield and Fritz Hansske at BioFocus DPI explore the revival of this approach |
|
|
| A new discovery technique welcomed by pharma and biotech alike goes under the spotlight in A Cohesive View of Fragments, by Mark Whittaker, Thomas Hesterkamp and John Barker at Evotec |
|
|
|
| Miroslav Reljanovic of Ergomed assesses some of the most promising management solutions - such as co-development deals - for efficiency and cost-saving in clinical trials, in A New Paradigm in Clinical Co-Development |
|
|
| In Generation X, Dr Adam Walker of Bioniqs Ltd outlines the development of ionic liquids - a burgeoning technology finding uses in natural product extraction, reactor cleaning and bio-catalysis |
|
|
| Adele Long at the BioMed Healthcare Technology Cooperative discusses recent collaborations aimed at improving treatments for an indication all too often relegated to 'Cinderella' status, in Healthcare Technology Cooperatives: Delivering Progress For Urinary Incontinence |
|
|
|
| Downstream purification carries the highest cost burden within the manufacturing process. Ligands are likely to play an increasing role in improving efficiency as efforts to create more stable, selective versions continue, says Phaedria M St Hilaire at VersaMatrix, in To Affinity and Beyond |
|
|
| As in so many areas of the industry, scrutiny is set to reach new levels in the field of process development, installing the concept of Quality by Design and changing industry practices and relationships. Bo Kara at Avecia Biotechnology charts the changes |
|
|
| In Bacterial Systems Breed New Expectation, Dr Søren M Madsen and Sean A MacDonald at Bioneer A/S urge the ongoing evolution of production solutions in order to meet the challenges of rising demand and variety |
|
|
|
| In EuroBiO: Meeting Europe's Potential in the Life Sciences, Axel Khan, EuroBiO President, explains the ethos behind the event, while Eric Poincelet, Commissioner General, gives a rundown of its highlights |
|
|
|
|
|
